Julio Casoy Joins InClinica as Chief Medical Officer
PHILADELPHIA (April 5, 2018) – InClinica, a global clinical CRO, announced that Julio Casoy has been appointed as Chief Medical Officer. In his new role, he will oversee all medical affairs for InClinica worldwide.
Dr. Casoy has more than 20 years of experience in the pharmaceutical industry, specializing in rheumatology with a long history of work in women’s health. Before joining InClinica, he served as Senior Vice President of Medical Affairs at Turing Pharmaceuticals where he was responsible for establishing and managing medical affairs including data generation, data dissemination, compliance, and KOL management. Prior to that, he oversaw the medical affairs of various pharmaceutical companies, most notably, spending more than a decade leading Wyeth’s international medical affairs in Brazil.
“Julio will make an excellent addition to the InClinica team, as we expand our operations globally,” said James Nolan, CEO at InClinica. “His wealth of experience in clinical research and medical affairs in both the U.S. and South America make him a perfect fit to oversee medical operations for our organization worldwide.
Dr. Casoy received a Bachelor of Science Degree in Internal Medicine with a specialization in Rheumatology from the Federal University of Sao Paulo, and his Master’s Degree in Health and Hospital Management from the Business Management School at the University of Sao Paulo Clinics Hospital.
InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Philadelphia with other locations in the U.K., Israel, and Malaysia/Singapore.